COMP <GO>
COAG vs NVAX // EV/EBITDA & P/E VALUATION
Hemab Therapeutics Holdings Inc. (NASDAQ) VS. Novavax Inc. (NASDAQ) • 15-METRIC TALLY: COAG 2
— NVAX 0
■ METRIC PARITY
LAST: $40.42 (+4.99%) • MKT CAP: $1.89B
valuation
—
LAST: $10.47 (+1.45%) • MKT CAP: $1.73B
valuation
3.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COAG VS. NVAX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COAG | NVAX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 93.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 85.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 3.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -14.17% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 40.30% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 39.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 64.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 5/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.2 | 44.9 | +22.30 | COAG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 3.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.89B | $1.73B | $161.1M | COAG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COAG REV | NVAX REV | COAG GROSS % | NVAX GROSS % | COAG FCF | NVAX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.12B | — | 93.5% | — | -$244.6M |
| FY 2024 | — | $682.2M | — | 70.3% | — | -$87.3M |
| FY 2023 | — | $983.7M | — | — | — | -$714.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COAG // BETA —
NVAX // BETA —